Skip to main content
Log in

The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Results of a 10 year follow-up study

  • Guest editor's introduction
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

In a study on 214 patients with primary breast cancer (median follow-up 8.5 yr, maximum follow-up 15 yr), EGF-R was negatively correlated to estrogen receptor and progesterone receptor, whereas no association was found with age, lymph node status, and tumor size. Initially, after a follow-up of 5 yr, there was a tendency to a significant association between EGF-R levels and tumor recurrence rate (p=0.08). Patients with tumors containing intermediate levels of EGF-R experienced a longer relapse-free survival (RFS) than did patients with tumors possessing lower or higher levels of EGF-R. This effect was most pronounced in the subgroup of patients with positive axillary lymph nodes. However, after 10 yr follow-up, this association appears to be lost (p=0.28) as shown in this update. A similar phenomenon was observed for the ER. While at 5 yr follow-up ER status had significant prognostic value (p=0.01), at 10 yr follow-up this significance also appears to be lost (p=0.40). However, tumor size, lymph node status, grade, and PgR status maintained significant prognostic value by univariate analysis.

Based on 40 separate studies comprising 5232 patients, the mean percentage of EGF-R positivity reported in breast cancer is 45% (range 14–91%). Nine out of 15 different studies showed in some way a significant negative association between EGF-R and RFS by univariate analysis, and 2 others showed a tendency to such a relationship. Of 7 studies applying multivariate analysis, two demonstrated an independent prognostic value of EGF-R for RFS and two others a tendency to a significant correlation, whereas three did not. It may be concluded that EGF-R status has more or less prognostic value in patients with primary breast cancer, but the prognostic power decreases with longer follow-up. Of great clinical significance is the association of EGF-R with hormone resistance. Therefore EGF-R status can be used for selection of type of treatment. Finally, EGF-R might be useful as a target for new treatment modalities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Stoschek CM, King LE: Role of epidermal growth factor in carcinogenesis. Cancer Res 46:1030–1037, 1986

    Google Scholar 

  2. Fitzpatrick SL, Brightwell J, Wittliff JL, Barrows GH, Schultz GS: Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen receptor and progestin receptor levels. Cancer Res 44:3448–3453, 1984

    Google Scholar 

  3. Sainsbury JRC, Sherbet GV, Farndon JR, Harris AL: Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet i:364–366, 1985

    Google Scholar 

  4. Neal DE, Bennett MK, Hall RR, Marsh C, Abel PD, Sainsbury JRC, Harris AL: Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumors. Lancet i:366–368, 1985

    Google Scholar 

  5. Yasui W, Hata J, Yokozaki H, Nakatani H, Ochiai A, Ito H, Tahara E: Interaction between epidermal growth factor and its receptor in progression of human gastric carcinoma. Int J Cancer 41:211–217, 1988

    Google Scholar 

  6. Dazzi H, Hasleton PS, Thatcher N, Barnes DM, Wilkes S, Swindell R, Lawson RA: Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival. Br J Cancer 59:746–749, 1989

    Google Scholar 

  7. Schneider M, Etienne MC, Dassonville O, Francoual M, Formento JL, Ramaioli A, Demard F, Milano G: Epidermal growth factor receptor in head and neck carcinoma: prognostic value as compared to the initial stage. Proc AACR 34:231 [abs 1380], 1993

    Google Scholar 

  8. Scambia G, Benedetti Panici P, Battaglia F, Ferrandina G, Baiocchi G, Greggi S, De Vincenzo R, Mancuso S: Significance of epidermal growth factor receptor in advanced ovarian cancer. J Clin Oncol 10:529–535, 1992

    Google Scholar 

  9. Van der Burg MEL, Henzen-Logmans SC, Foekens JA, Berns PMJJ, Rodenburg CJ, van Putten WLJ, Klijn JGM: The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study. Eur J Cancer 29A:1951–1957, 1993

    Google Scholar 

  10. Klijn JGM, Berns PMJJ, Schmitz PIM, Foekens JA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 13:3–17, 1992

    Google Scholar 

  11. Klijn JGM, Berns PMJJ, Schmitz PIM, Foekens JA: Epidermal growth factor receptor (EGF-R) in clinical breast cancer: update 1993. Endocr Rev Monographs 1:171–174, 1993

    Google Scholar 

  12. Foekens JA, Portengen H, van Putten WLJ, Trapman AMAC, Reubi J-C, Alexieva-Figusch J, Klijn JGM: Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49:7002–7009, 1989

    Google Scholar 

  13. Rios MA, Fernandez A, Tormo B, Quintero S, Perez I, Skoog L, Perez R: Heterogenous expression of the EGF-receptor in human breast carcinoma. Anticancer Res 12:205–208, 1992

    Google Scholar 

  14. Benraad ThJ, Foekens JA: Hydroxylapatite assay to measure epidermal growth factor receptor in human primary breast tumors. Ann Clin Biochem 27:272–273, 1990.

    Google Scholar 

  15. Koenders PG, Faverly D, Beex LV, Bruggink ED, Kienhuis CB, Benraad TJ: Epidermal growth factor receptors in human breast cancer: a plea for standardisation of assay methodology. Eur J Cancer 28:693–697, 1992

    Google Scholar 

  16. Kienhuis CBM, Heuvel JJTM, Ross HA, Swinkels LMJW, Foekens JA, Benraad ThJ: Six methods for direct radioiodination of mouse epidermal growth factor compared: Effect of non-equivalence in binding behaviour between labeled and unlabeled ligand. Clin Chem 37:1749–1755, 1991

    Google Scholar 

  17. McGuire WL: Breast cancer prognostic factors. Editorial. J Natl Cancer Inst 83:154–155, 1991

    Google Scholar 

  18. Nicholson S, Sainsbury JRC, Halcrow P, Chambers P, Farndon JR, Harris AL: Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet i:182–184, 1989

    Google Scholar 

  19. Nicholson S, Wright C, Sainsbury JRC, Halcrow P, Kelly P, Angus B, Farndon JR, Harris AL: Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure. J Steroid Biochem Molec Biol 37:811–815, 1990

    Google Scholar 

  20. Wright C, Nicholson S, Angus B, Sainsbury JR, Farndon J, Cairns J, Harris AL, Horne CH: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118–121, 1992

    Google Scholar 

  21. Klijn JGM, Berns PMJJ, Bontenbal M, Foekens JA: Cell biological factors associated with the response of breast cancer to systemic treatment. Cancer Treat Rev 19 (Suppl B):45–63, 1993

    Google Scholar 

  22. Klijn JGM, Berns PMJJ, Foekens JA: Prognostic factors and response to therapy in breast cancer. Cancer Surveys, in press, 1993

  23. Grimaux M, Romain S, Remvikos Y, Martin PM, Magdelenat H: Prognostic value of epidermal growth factor receptor in node-positive breast cancer. Breast Cancer Res Treat 14:77–90, 1989

    Google Scholar 

  24. Nicholson S, Sainsbury JRC, Halcrow P, Kelly P, Angus B, Wright C, Henry J, Farndon JR, Harris AL: Epidermal growth factor receptor (EGFr): results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 63:146–150, 1991

    Google Scholar 

  25. Kinsel LB, Szabo E, Greene GL, Konrath J, Leight GS, McCarty KS Jr: Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res 49:1052–1056, 1989

    Google Scholar 

  26. Alexieva-Figusch J, van Putten WLJ, Blankenstein MA, Blonk-van der Wijst J, Klijn JGM: The prognostic value and relationships of patient characteristics, progestin receptor, estrogen receptor, and site of relapse in primary and metastatic human breast cancer. Cancer 61:758–768, 1988

    Google Scholar 

  27. Van Agthoven T, Van Agthoven TLA, Portengen H, Foekens JA, Dorssers LCJ: Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res 52:5082–5088, 1992

    Google Scholar 

  28. Long B, McKibben BM, Lynch M, Van den Berg HW: Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line. Br J Cancer 65:865–869, 1992

    Google Scholar 

  29. de Fazio A, Chiew YE, Donoghue C, Lee CS, Sutherland RL: Effect of sodium butyrate on estrogen receptor and epidermal growth factor receptor gene expression in human breast cancer cell lines. J Biol Chem 267:18008–18012, 1992

    Google Scholar 

  30. Klijn JGM, Berns PMJJ, Bontenbal M, Alexieva-Figusch J, Foekens JA: Clinical breast cancer, new developments in selection and endocrine treatment of patients. J Steroid Biochem Mol Biol 43:211–221, 1992

    Google Scholar 

  31. Harris AL: The epidermal growth factor receptor as a target for therapy. Cancer Cells 2:321–323, 1990

    Google Scholar 

  32. Mendelsohn J: Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. Monogr Natl Cancer Inst 13:125–131, 1992

    Google Scholar 

  33. Manni A, Wright C, Buck H: Growth factor involvement in the multihormonal regulation of MCF-7 breast cancer cell growth in soft agar. Breast Cancer Res Treat 20:43–52, 1991

    Google Scholar 

  34. Reddy KB, Mangold GL, Tandon AK, Yoneda T, Mundy GR, Zilberstein A, Osborne CK: Inhibition of breast cancer cell growthin vitro by a tyrosine kinase inhibitor. Cancer Res 52:3636–3641, 1992

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klijn, J.G.M., Look, M.P., Portengen, H. et al. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Results of a 10 year follow-up study. Breast Cancer Res Tr 29, 73–83 (1994). https://doi.org/10.1007/BF00666183

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00666183

Key words

Navigation